- |||||||||| Neulasta (pegfilgrastim) / Roche, Rituxan (rituximab) / Roche
New P2 trial, Combination therapy: Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma (clinicaltrials.gov) - Sep 6, 2012 P2, N=20, Active, not recruiting,
- |||||||||| dilanubicel (NLA101) / Nohla Therap
Enrollment closed, Combination therapy: Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Sep 3, 2012 P1, N=40, Active, not recruiting, Recruiting --> Active, not recruiting Suspended --> Active, not recruiting
- |||||||||| motesanib (AMG 706) / Takeda
Trial termination, Combination therapy, Metastases: MONET1-MOtesanib NSCLC Efficacy and Tolerability Study (clinicaltrials.gov) - Aug 12, 2012 P3, N=1450, Terminated, Not yet recruiting --> Recruiting Active, not recruiting --> Terminated; Amgen discontinued the development of AMG706 because 20050201 did not meet its primary objective.
- |||||||||| Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
Clinical: TNF-alfa Inhibitors and Antibody Production in Patients With Psoriasis (clinicaltrials.gov) - Aug 2, 2012 P=N/A, N=60, Recruiting,
|